Cycloserine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SEROMYCIN | — | 1964-06-29 | fda.gov ↗ |
Trials 100 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials · 2 missed | ||||||
| Phase 0 | NCT07785102 | Sep → Dec 2026 expected | major depressive disorder | Mclean Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07560878 | Mar 2026 → Dec 2030 expected | major depressive disorder | Mclean Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT04357951 | Apr 2023 → Mar 2024 | Tourette syndrome | Johns Hopkins University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03780829 | Feb 2020 → Feb 2026 | — | VA Office of Research and Development | Terminated | No outcome recorded Stop: Business |
| Phase 0 | NCT02304432 | Sep 2015 → Sep 2016 | bipolar disorder, schizophrenia | Mclean Hospital | Completed | No outcome recorded |
| Phase 0 | NCT02066792 | Apr 2014 → Jul 2018 | social phobia | Jasper A. Smits | Completed | Missed primary |
| Phase 0 | NCT01944423 | Oct 2013 → Oct 2018 | nicotine dependence, panic disorder | University of Texas at Austin | Completed | Missed primary |
| Phase 0 | NCT02312635 | Dec 2012 → Sep 2016 | traumatic brain injury | University of California, Los Angeles | Unknown | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT05731323 | Oct 2022 → Jun 2023 | major depressive disorder | University of Calgary | Completed | No outcome recorded |
| Phase 1 | NCT03511599 | Sep 2018 → Dec 2020 | major depressive disorder | University of Calgary | Completed | No outcome recorded |
| Phase 1 | NCT03432689 | Aug → Nov 2018 | — | University of Calgary | Completed | No outcome recorded |
| Phase 1 | NCT02099825 | Jan 2014 → Oct 2022 | anxiety disorder | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT02769936 | Nov 2013 → Jul 2015 | schizophrenia | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT02128308 | Nov → Dec 2013 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01068847 | Feb 2010 → Oct 2012 | drug dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT00733239 | Aug 2008 → Oct 2010 | opiate dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT00593463 | Sep 2006 → May 2010 | drug dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07593222 | Jul 2026 → Dec 2030 expected | major depressive disorder | Mclean Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07460947 | Jun 2026 → Jun 2027 expected | borderline personality disorder | Mclean Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01923896 | Mar → Sep 2013 | eating disorder, specific phobia | Emory University | Completed | No outcome recorded |
| Phase 229 trials · 3 met primary · 2 missed | ||||||
| Phase 2 | NCT07868627 | Jun 2025 → Dec 2026 expected | anxiety, depressive disorder | Mclean Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06128213 | Mar → Jun 2024 | pyelonephritis | NeuroRx, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT06121284 | Mar 2024 → Jul 2026 overdue | mixed anxiety and depressive disorder | University of Calgary | Recruiting | No outcome recorded |
| Phase 2 | NCT05994703 | Oct 2023 → Oct 2025 | — | Rose Research Center, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05395494 | Aug 2022 → Jul 2025 | fibromyalgia | University of Calgary | Terminated | Missed primary |
| Phase 2 | NCT05081986 | Aug → Oct 2021 | — | University of Calgary | Completed | No outcome recorded |
| Phase 2 | NCT04035603 | Oct 2020 → Jan 2021 | — | Boston University Charles River Campus | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03937596 | Dec 2019 → Dec 2020 | major depressive disorder | University of Calgary | Completed | Met primary |
| Phase 2 | NCT03535688 | Mar 2018 → Feb 2024 | — | Northwestern University | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02974010 | Jan → Aug 2018 | bipolar depression | NeuroRx, Inc. | Completed | Met primary |
| Phase 2 | NCT02933684 | Jan 2015 → Dec 2016 | social phobia | Georgia State University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00125528 | Jul 2012 → Apr 2014 | — | Thomas J. Schnitzer | Completed | Missed primary |
| Phase 2 | NCT01928823 | Nov 2011 → May 2014 | agoraphobia | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2 | NCT01526538 | Sep 2011 → Mar 2013 | cocaine dependence | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT01343862 | Aug 2011 → May 2014 | traumatic brain injury | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 2 | NCT02082912 | Jun 2010 → Apr 2012 | stroke disorder | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT00720759 | Jul 2009 → Nov 2011 | stroke disorder | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 2 | NCT00869765 | Apr 2009 → Sep 2010 | bipolar disorder, major depressive disorder | The University of New South Wales | Completed | No outcome recorded |
| Phase 2 | NCT00759473 | Sep 2008 → Oct 2011 | substance-related disorder | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT00827281 | Aug 2008 → Jul 2015 | — | Boston University Charles River Campus | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT00790868 | Apr 2008 → Aug 2014 | panic disorder | Boston University Charles River Campus | Completed | Met primary |
| Phase 2 | NCT01361633 | Jan 2008 → Feb 2009 | — | Hartford Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00864123 | Jan 2008 → Nov 2009 | obsessive-compulsive disorder | University of South Florida | Completed | No outcome recorded |
| Phase 2 | NCT00430573 | Feb 2007 → Jun 2009 | substance-related disorder | Boston University Charles River Campus | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00408031 | Jan 2007 → May 2010 | major depressive disorder | Herzog Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00780442 | Sep 2006 → Jul 2008 | cocaine dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT00591825 | Mar 2006 → Dec 2012 | phobic disorder | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00257361 | Jul 2005 → ? | obsessive-compulsive disorder | University of Florida | Withdrawn | No outcome recorded |
| Phase 2 | NCT00000194 | Jan 1993 → Jan 1998 | substance-related disorder | Yale University | Withdrawn | No outcome recorded |
| Phase 2/36 trials · 2 missed | ||||||
| Phase 2/3 | NCT07227103 | Sep 2026 → Dec 2027 expected | atypical depressive disorder | NeuroRx, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03395392 | May 2022 → Feb 2024 | bipolar depression | NeuroRx, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT03216356 | Sep 2016 → Dec 2023 | post-traumatic stress disorder | Boston University Charles River Campus | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00452231 | Feb 2007 → Jul 2008 | post-traumatic stress disorder | University of Montreal | Unknown | No outcome recorded |
| Phase 2/3 | NCT00356278 | Sep 2006 → Jun 2014 | post-traumatic stress disorder | Emory University | Completed | Missed primary |
| Phase 2/3 | NCT00222235 | Jan 2000 → Jun 2004 | schizoaffective disorder, schizophrenia | University of Maryland, Baltimore | Completed | Missed primary |
| Phase 311 trials · 2 missed | ||||||
| Phase 3 | NCT05081401 | May 2022 → Dec 2026 expected | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT03396068 | Dec 2019 → Dec 2024 | bipolar depression | NeuroRx, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT03416621 | May 2018 → Feb 2020 | nicotine dependence | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT01680107 | Oct 2012 → Oct 2017 | panic disorder | University of Oxford | Terminated | No outcome recorded |
| Phase 3 | NCT01411774 | Jun 2011 → Jun 2016 | obsessive-compulsive disorder | University of South Florida | Completed | No outcome recorded |
| Phase 3 | NCT01102803 | Apr 2010 → Jul 2011 | phobic disorder | Southern Methodist University | Completed | Missed primary |
| Phase 3 | NCT01086475 | Mar 2010 → Jan 2014 | autism | Indiana University | Completed | Mixed |
| Phase 3 | NCT00515879 | Dec 2007 → Dec 2011 | social phobia | Boston University Charles River Campus | Completed | No outcome recorded |
| Phase 3 | NCT00198120 | Feb 2004 → Sep 2007 | autism | Indiana University | Completed | No outcome recorded |
| Phase 3 | NCT00000372 | Mar 1998 → Nov 2005 | schizophrenia | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT00000371 | Aug 1996 → Apr 2002 | schizophrenia | Massachusetts General Hospital | Completed | Missed primary |
| Phase 415 trials · 1 met primary · 4 missed | ||||||
| Phase 4 | NCT07542548 | Jul 2024 → Mar 2026 | hereditary spastic paraplegia | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03867136 | Jun 2020 → Aug 2024 | multidrug-resistant tuberculosis | Huashan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03830671 | Mar 2019 → Jun 2022 | multidrug-resistant tuberculosis | Beijing Chest Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03237182 | Jun 2017 → Dec 2022 | multidrug-resistant tuberculosis | Centre for the AIDS Programme of Research in South Africa | Terminated | No outcome recorded |
| Phase 4 | NCT02772211 | Jun → Dec 2016 | — | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02656342 | Nov 2015 → Sep 2018 | obsessive-compulsive disorder | Haukeland University Hospital | Completed | Missed primary |
| Phase 4 | NCT01981759 | Feb 2014 → May 2017 | delusional disorder, schizoaffective disorder, schizophrenia | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT02385266 | Sep 2013 → May 2016 | chronic prostatitis | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01833897 | Mar 2013 → Jul 2014 | bipolar disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT01649895 | Aug 2012 → Jun 2016 | obsessive-compulsive disorder | Christian Rück | Completed | Missed primary |
| Phase 4 | NCT00964041 | Jul 2009 → Jun 2011 | schizophrenia | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT01490697 | Mar 2009 → Sep 2015 | post-traumatic stress disorder | Roger K. Pitman, MD | Completed | Missed primary |
| Phase 4 | NCT00674570 | Jan 2009 → Jun 2015 | post-traumatic stress disorder | VA Office of Research and Development | Completed | Met primary |
| Phase 4 | NCT00742079 | Sep 2006 → Jul 2010 | schizophrenia | Massachusetts General Hospital | Completed | Missed primary |
| Phase 4 | NCT00455702 | Jul 2004 → Apr 2007 | schizophrenia | Massachusetts General Hospital | Completed | Mixed |
| Phase not applicable18 trials · 1 met primary · 1 missed | ||||||
| — | NCT04762836 | Feb → Aug 2021 | chronic pain syndrome | Leiden University Medical Center | Completed | No outcome recorded |
| — | NCT04717908 | Jan 2021 → Jun 2024 | multidrug-resistant tuberculosis | Huashan Hospital | Completed | No outcome recorded |
| — | NCT04545788 | Aug 2020 → Dec 2022 | tuberculosis | Beijing Chest Hospital | Unknown | No outcome recorded |
| — | NCT03961464 | Aug → Dec 2018 | — | University of Oxford | Completed | No outcome recorded |
| — | NCT02582515 | Oct 2015 → Aug 2017 | Tourette syndrome, chronic tic disorder | University of California, Los Angeles | Completed | No outcome recorded |
| — | NCT01996644 | Feb 2013 → Feb 2014 | eating disorder | Washington University School of Medicine | Completed | Met primary |
| — | NCT01450306 | Jul 2010 → Dec 2011 | specific phobia | Hartford Hospital | Completed | No outcome recorded |
| — | NCT01067846 | Jun 2010 → Jan 2012 | cocaine dependence | University of Arkansas | Completed | No outcome recorded |
| — | NCT00963924 | Aug 2009 → May 2011 | schizophrenia | Massachusetts General Hospital | Completed | Mixed |
| — | NCT01037101 | Jul 2009 → Dec 2014 | — | CAMC Health System | Unknown | No outcome recorded |
| — | NCT00855153 | May 2009 → Nov 2011 | post-traumatic stress disorder | United States Army Institute of Surgical Research | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00875342 | May 2008 → Feb 2018 | post-traumatic stress disorder | Weill Medical College of Cornell University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00633256 | Dec 2006 → Feb 2008 | — | Yale University | Completed | No outcome recorded |
| — | NCT00371176 | Oct 2006 → Sep 2011 | combat disorder, post-traumatic stress disorder | US Department of Veterans Affairs | Completed | Missed primary |
| — | NCT00632632 | Jan 2005 → Dec 2012 | post-traumatic stress disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| — | NCT00131339 | Nov 2004 → Mar 2007 | panic disorder | Hartford Hospital | Completed | No outcome recorded |
| — | NCT00126282 | Dec 2003 → Dec 2007 | obsessive-compulsive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT00000796 | ? → Oct 1998 | HIV infectious disease, pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05779267 | — | — | NeuroRx, Inc. | Available | No outcome recorded |
| Comparator or background therapy35 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT01985750 Comparator | Nov 2013 → Dec 2018 | chronic obstructive pulmonary disease | University of Oxford | Unknown | No outcome recorded |
| Phase 0 | NCT00842309 Comparator | Nov 2008 → Dec 2017 | body dysmorphic disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02735694 Comparator | Sep 2015 → Jun 2016 | sleep apnea syndrome | University of Manitoba | Terminated | No outcome recorded |
| Phase 1 | NCT01062932 Comparator | May 2009 → May 2010 | nicotine dependence | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT05591677 Comparator | Apr 2023 → May 2026 overdue | major depressive disorder | The Alfred | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05177601 Comparator | Nov 2021 → Oct 2024 | obsessive-compulsive disorder | University of Calgary | Unknown | No outcome recorded |
| Phase 2 | NCT02983734 Comparator | Oct 2015 → Sep 2019 | persian gulf syndrome | Boston University Charles River Campus | Completed | No outcome recorded |
| Phase 2 | NCT02365623 Background | Feb 2015 → Nov 2018 | multidrug-resistant tuberculosis | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 2 | NCT01907594 Comparator | Aug 2013 → May 2015 | — | New York State Psychiatric Institute | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT01687140 Comparator | Jul 2012 → Jul 2014 | obsessive-compulsive disorder | University of California, Los Angeles | Unknown | No outcome recorded |
| Phase 2 | NCT01157416 Comparator | Jun 2010 → Jun 2012 | post-traumatic stress disorder | Tulane University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01157429 Comparator | Jun 2010 → Jun 2012 | post-traumatic stress disorder | Tulane University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00128401 Comparator | Aug 2005 → Jun 2012 | anxiety, social phobia | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2/3 | NCT00926900 Comparator | Mar 2009 → Apr 2012 | alcohol dependence | Central Institute of Mental Health, Mannheim | Unknown | No outcome recorded |
| Phase 3 | NCT06081361 Comparator | Dec 2023 → Oct 2026 expected | pulmonary tuberculosis, rifampicin-resistant tuberculosis | Beijing Chest Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02975570 Comparator | Aug 2017 → Aug 2021 | multidrug-resistant tuberculosis | Boston University | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT01352637 Comparator | May 2011 → Sep 2018 | post-traumatic stress disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 3 | NCT01399866 Comparator | May 2011 → Oct 2013 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00301080 Comparator | Feb 2006 → Feb 2007 | breast cancer, toxic polyneuropathy | Northwestern University | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00198107 Comparator | Sep 2005 → Sep 2011 | autism spectrum disorder | Indiana University | Completed | No outcome recorded |
| Phase 3 | NCT00182000 Comparator | Nov 2003 → Jan 2008 | obsessive-compulsive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT07145866 Comparator | Jul 2026 → Sep 2028 expected | nicotine dependence | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05306223 Background | May 2022 → Aug 2025 | multidrug-resistant tuberculosis | Beijing Chest Hospital | Unknown | Met primary |
| Phase 4 | NCT02635893 Comparator | Jun 2019 → Mar 2021 | spinal cord injury | Shirley Ryan AbilityLab | Completed | No outcome recorded |
| Phase 4 | NCT00633984 Comparator | Mar 2007 → Mar 2012 | social phobia | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT07198685 Comparator | Sep 2025 → Sep 2027 expected | — | Wuhan Pulmonary Hospital | Not yet recruiting | No outcome recorded |
| — | NCT03604848 Comparator | Aug 2018 → Aug 2024 | multidrug-resistant tuberculosis | Huashan Hospital | Unknown | No outcome recorded |
| — | NCT03062150 Comparator | Sep 2016 → Feb 2019 | major depressive disorder | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT02687165 Comparator | Jan 2016 → Jan 2017 | chronic pain syndrome, post-treatment Lyme disease syndrome | New York State Psychiatric Institute | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01404208 Comparator | Jul 2011 → Sep 2015 | obsessive-compulsive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT01362309 Comparator | Nov 2010 → Oct 2012 | alcohol-related disorders | University of Georgia | Completed | No outcome recorded |
| — | NCT01172873 Comparator | Sep 2008 → Sep 2010 | obsessive-compulsive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| — | NCT00635102 Comparator | Oct 1997 → Feb 2008 | alcohol dependence | Yale University | Completed | No outcome recorded |
| — | NCT01512316 Comparator | — | — | Universitaire Ziekenhuizen KU Leuven | Withdrawn | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 145 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cycloserine | “anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS],...” NCT02365623 ↗27“Experimental arms are seven oral regimens with a five-drug combination of the following: bedaquiline, linezolid, a fluoroquinolone (moxifloxacin or levofloxacin), cycloserine,...” NCT05081401 ↗ “This is a pilot study investigating if cycloserine (DCS; a learning enhancement medication) augments exposure therapy for food anxiety in patients with anorexia and bulimia nervosa.” NCT01996644 ↗ “The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid” NCT03830671 ↗ “D-cycloserine (seromycin) is a broad spectrum antibiotic, in use for over thirty years in the treatment of tuberculosis” NCT02772211 ↗ “D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd” NCT03062150 ↗ “either cycloserine or para-aminosalicylic acid, with preference for cycloserine” NCT02975570 ↗ “Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily” NCT03604848 ↗ “Cycloserine: 500, 675, 750 mg oral capsule may possibly be given” NCT00733239 ↗ “Cycloserine: 500, 675, 750 mg oral capsules may possibly given.” NCT01068847 ↗ “Cycloserine ≤50kg 500 mg daily, \>50kg 750mg daily” NCT03867136 ↗ |
| Known as | Cicloserina | ChEMBL registry synonym — accepted as the source's own label CHEMBL771 ↗ |
| Known as | Cs-Cycloserine | “The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid” NCT03830671 ↗ |
| Known as | CYC | “The present study examined the impact of the N-type calcium channel blocker gabapentin (GBP) and the partial glycine agonist D-cycloserine (CYC) to attenuate the behavioral...” PMID 40272204 ↗ Apr 2025 |
| Known as | Cycloserine: Seromycin | “Cycloserine: Seromycin” NCT01068847 ↗ |
| Known as | Cycloserinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL771 ↗ |
| Known as | D-Cyclocerine | “D-Cyclocerine, a partial N-methyl-Daspartate (NMDA) receptor agonist, enhances extinction of learned fear among rats2” NCT01687140 ↗ |
| Known as | d-cycloserine | “The present study examined the impact of the N-type calcium channel blocker gabapentin (GBP) and the partial glycine agonist D-cycloserine (CYC) to attenuate the behavioral...” PMID 40272204 ↗ Apr 2025119“An exciting recent finding from animal research is the ability of an established antibiotic (traditionally used to treat Tuberculosis), D-cycloserine (trade name: Seromycin) to...” NCT01687140 ↗ “D-Cycloserine is a glutamatergic N-methyl-d-aspartate receptor agonist that has been shown to facilitate the benefits of exposure therapy for anxiety disorders by enhancing the...” PMID 26132687 ↗ Jun 2015 “Arm 3)will include a combination of cognitive behavioral cessation counseling, enhanced cue exposure treatment (lab-based + interactive SMS texting) and a cognitive-enhancing...” NCT03416621 ↗ “d-Cycloserine (DCS) enhances extinction learning across species, but it has proven challenging to identify consistent benefit of DCS when added to therapeutic interventions.” PMID 28138381 ↗ Jan 2017 “Combat veterans with PTSD underwent 6 weeks of VR exposure therapy combined with either d-cycloserine (DCS), alprazolam (ALP), or placebo (PBO).” PMID 27183343 ↗ May 2016 “This study examines whether an antibiotic, d-cycloserine (DCS), boosts the effectiveness of cognitive behavior therapy (CBT) for social anxiety.” NCT00128401 ↗ “The purpose of this study is to test a drug called d-cycloserine to see if it can help people with a condition called social phobia.” NCT00633984 ↗ “NRX-101 is composed of D-cycloserine (DCS) an NMDA antagonist and lurasidone (5HT2a atypical antipsychotic and antidepressant).” NCT03395392 ↗ “This medicine - D-Cycloserine - is actually an antibiotic, currently FDA approved for the treatment of tuberculosis.” NCT02687165 ↗ “participants will randomly receive either 100mg of d-cycloserine (DCS, an antibiotic) or a placebo capsule” NCT03511599 ↗ |
| Known as | D-cycloserine, DCS | “D-cycloserine, DCS” NCT02066792 ↗1“d-cycloserine; DCS” NCT01944423 ↗ |
| Known as | D-Cyloserine | “Our neurophysiological data and clinical data in depression suggests that we can enhance the effects of TMS by using an adjunctive medication called D-Cyloserine (DCS, 100mg)...” NCT05177601 ↗ |
| Known as | DCS | “The two medications are (1) d-cycloserine (DCS), a medication that is an agonist (facilitator) of the NMDA glutamatergic receptor and has been shown in previous studies to...” NCT02099825 ↗47“This is a single site, open-label, feasibility study of cognitive behavioral therapy with exposure and response prevention (CBT/ERP) adding the augmentation of D-cycloserine...” NCT01172873 ↗ “NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of D-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar...” NCT03396068 ↗ “D-Cycloserine (DCS) is a partial NMDA receptor agonist that has been shown to enhance therapeutic response to exposure-based treatments for anxiety disorders, but has not been...” PMID 22694905 ↗ Jun 2012 “The investigators hope to boost the clinical response to smoking cue exposure therapy in quitters on NRT (nicotine replacement therapy) pretreatment by pharmacological...” NCT01907594 ↗ “Our neurophysiological data and clinical data in depression suggests that we can enhance the effects of TMS by using an adjunctive medication called D-Cyloserine (DCS, 100mg)...” NCT05177601 ↗ “This is a pilot study investigating if cycloserine (DCS; a learning enhancement medication) augments exposure therapy for food anxiety in patients with anorexia and bulimia nervosa.” NCT01996644 ↗ “D-cycloserine (DCS): A medication originally developed as an antibiotic that, at lower doses, helps brain cells form new connections and learn more effectively (neuroplasticity).” NCT07868627 ↗ “We have shown that targeting the NMDA receptor with low doses of the partial agonist, D-cycloserine (DCS), normalizes long-term motor cortex plasticity in individuals with MDD.” NCT07227103 ↗ “d-Cycloserine (DCS) enhances extinction learning across species, but it has proven challenging to identify consistent benefit of DCS when added to therapeutic interventions.” PMID 28138381 ↗ Jan 2017 “This pilot study aims evaluate the feasibility and initial efficacy of behavior therapy augmented by d-cycloserine (DCS) compared to behavior therapy augmented by placebo.” NCT04357951 ↗ |
| Known as | NSC-154851 | ChEMBL registry synonym — accepted as the source's own label CHEMBL771 ↗ |
| Known as | NSC-76029 | ChEMBL registry synonym — accepted as the source's own label CHEMBL771 ↗ |
| Known as | Orientomycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL771 ↗ |
| Known as | Seromycin | “An exciting recent finding from animal research is the ability of an established antibiotic (traditionally used to treat Tuberculosis), D-cycloserine (trade name: Seromycin) to...” NCT01687140 ↗8“One group of participants will receive the medication cycloserine (seromycin) and one group will receive a placebo drug (like a sugar pill).” NCT00632632 ↗ “D-cycloserine (seromycin) is a broad spectrum antibiotic, in use for over thirty years in the treatment of tuberculosis” NCT02772211 ↗ “Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.” NCT01067846 ↗ “D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis” NCT00408031 ↗ “Daily oral D-cycloserine 100mg during TMS treatments (20 days). Other Names: Seromycin” NCT05395494 ↗ “Drug Trade Name--Seromycin, (D-cycloserine)” NCT02312635 ↗ |
| Known as | Seromycin (d-cycloserine) | “Seromycin (d-cycloserine)” NCT02304432 ↗ |
| Action | Activate | “enhancing NMDA receptor function by systemic treatment with D-cycloserine” NCT00000371 ↗ |
| Modality | Small molecule | — CHEMBL771 ↗ |
| Route | Oral | “50 mg/daily by mouth” NCT00000371 ↗ |